Recent News

• 06.07.2026 - LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
• 05.26.2026 - LENZ Therapeutics to Participate in Upcoming Investor Conferences
• 05.11.2026 - LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
• 05.04.2026 - LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
• 04.20.2026 - LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
• 03.24.2026 - LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Recent Filings

• 05.11.2026 - 8-K Current report
• 05.11.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.11.2026 - EX-99.1 EX-99.1
• 04.28.2026 - DEF 14A Other definitive proxy statements
• 04.28.2026 - ARS Annual Report to Security Holders
• 04.28.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.27.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.08.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.30.2026 - 4 Statement of changes in beneficial ownership of securities